# **Deloitte.**



# Is it time for life sciences organizations to pivot?

## How life sciences organizations are learning from the technology sector to reimagine business models by 2040

Health in 2040 will be a world apart from what we have now. <u>Our future of biopharma<sup>1</sup></u> and <u>future of medtech<sup>2</sup></u> predictions project accelerated change across multiple industry use cases and the potential for completely disrupted business models. This paper outlines ways for life sciences (LS) organizations to thrive, inspired by industries that have undergone similar change. We specifically focus on industry convergence—the process of two or more industries coming together.

Convergence is not a novel concept; indeed, numerous industries have converged over the past two decades. It is exogenous shocks like COVID-19 or the 2008 financial crisis, combined with technological advancements, that accelerate it. Given other industries' rapid, technology-driven convergence, the combination of COVID-19 and a challenging economic backdrop should drive the same, long-overdue shift for LS.

Luckily, although it's disruptive, convergence has delivered significant benefits for industries and their customers—the "best of both worlds." If anything, convergence should prompt organizations to capitalize and accelerate innovation, responding, recovering, and thriving in times of uncertainty. Convergence will allow LS to leapfrog the standard of care available to most patients.

#### What is convergence?

Two industries coming together, where the incumbent industry is disrupted as the challenger industry aims to serve the needs it previously served (e.g., digital therapeutics start-ups entering healthcare & life sciences). The disruptor industry often serves industry needs via a new operating or delivery model



#### What is not convergence?

Two industries coming together, where the challenger industry provides upstream or downstream services to the incumbent industry (e.g., Google providing Cloud Services to healthcare & life sciences companies). An industry being disrupted by advancements within the industry itself (e.g., scientific innovation in life sciences, gene editing for example) is also not considered convergence



When looking at convergence in other industries, retail stands out. Technological advances responded to customer demand for digital retail orders at the lowest possible prices with e-commerce, whose rise has forced incumbents to radically shift the way they engage with consumers.


Another dislocation occurred in advertising, where tech giants' entirely new advertising paradigm disrupted print, TV, and radio ad markets. By collecting more data and using analytics tools for meaningful insights, they have been able to identify more customers and drive sales.

Similarly, LS and health care (HC) are increasingly witnessing convergence, with COVID-19 forcing incumbents to reconsider their product development, use technology to enhance the patient experience, and address unmet patient needs. All the while, tech firms are making explicit, systematic moves to enter LS and HC,<sup>3</sup> placing imminent pressure on incumbents to respond—strategies for which will be discussed further in this paper.

#### Drivers and headwinds of convergence in LS and HC

LS and HC have already witnessed early signs of convergence, particularly in the increasing pace of technological adoption. Companies are building and incorporating digital tools and digital biomarkers in drug development and developing clinical decision support tools for HC practitioners.

Current macroeconomic and competitive dynamics have made LS ripe for disruption (figure 2), which was only accelerated by COVID-19 and the widespread adoption of virtual care. The compounding effect of these drivers will increasingly spur cross-industry convergence. In order to remain competitive, LS companies will need to evolve their internal capabilities, product mix, technology solutions, and partnerships creatively. Thus, cross-industry convergence will unlock new markets and revenue sources required in the "new normal."




Though convergence as a growth mechanism is increasing in LS, the industry's operations have yet to change radically, with no true "paradigm shift" in how LS delivers value to patients. Most resources remain invested in high-value therapeutic interventions rather than diagnostics and prevention. While LS companies are buoyed by the above drivers, they must acknowledge and prepare for potential headwinds against industry expansion. Two of the most salient in LS and HC are delays in technology adoption and regulatory complexities.


**Technology adoption:** Disruptors have found HC institutions hesitant to be first adopters of new procedures and technologies, possibly due to institution-specific factors (e.g., disadvantageous reimbursement plans, required behavioral changes, or physician training) or the type of technology being introduced. Exogenous events, such as COVID-19–related travel restrictions, are often the greatest catalyst of adoption of new technologies (e.g., telehealth and real-time and remote monitoring).

**Regulatory complexities of product development:** The need to meet high standards of efficacy and safety in the regulatory approval process creates unique hurdles for LS product commercialization, which can be particularly challenging for companies looking to bring new and untested products to market. Industry incumbents typically have rigorous processes and experienced teams dedicated to navigating regulatory approval pathways in a structured manner, but disruptive companies without similar resources and expertise may require third-party support or incumbent partnership.

Nevertheless, LS continues to provide an attractive investment backdrop due to its large profit pool, unmet needs, and well-capitalized incumbents with a propensity for M&A. As a result, we believe venture capital deployed in the space will continue to grow, as will the appetite for risk.

Overall, convergence in LS, triggered by COVID-19, is increasingly evident. Growth in the volume of cross-industry LS deals reflects marketwide response to the driving factors behind convergence. Figure 3 provides a 10-year snapshot of cross-industry deal volume involving LS buyers. The number of such deals has nearly doubled in the past five years, from 185 (2010–2014) to 338 (2015–2019)<sup>4</sup>.






Cross-industry M&A deals as % of total life sciences deal volume

Source: Deloitte Source: Deloitte analysis; Crunchbase

#### **Convergence in action**

Convergence will be experienced across multiple domains in LS, changing how therapeutic interventions are discovered and how patients receive care. Technological convergence looks apt to imminently shift the existing paradigm in five domains.



#### **Drug development and screening**

For decades, the drug discovery process has remained static. Researchers identify potential targets, create compounds, and progress development from lab animals to humans. However, screening and development is undergoing a revolution thanks to artificial intelligence and machine learning (AI/ML). In silico drug development (the process of discovering new targets via bioinformatic tools) is gaining traction, and as it continues to gain steam, we anticipate a greater role for tech companies, given their expertise in AI and machine learning models. In late 2019, the first-ever AI-discovered drug was moved into clinical development, with preclinical development shortened from four years to just 18 months.<sup>4</sup> New challengers proficient in ML and statistical analysis are entering the market, funded by venture capital and able to acquire resources for product approval.

COVID-19 has provided an immediate catalyst for AI adoption. Scientists rapidly created 3D models of SARS-CoV-2 proteins to visualize and create compounds and vaccines to fight the virus<sup>5</sup>. It took about two months to accurately understand the structure of the SARS-CoV main protease in 2003; in 2020, it took only one week<sup>6</sup>. With increased confidence in the ability to quickly break down virus structures, drug development should accelerate.

#### **Digital therapeutics**

We have previously outlined our perspective on digital therapeutics<sup>7</sup>, an emerging treatment for chronic diseases with proven clinical outcomes outside classic care delivery models.

Digital therapeutics are challenging the historical disease- and symptom-management paradigm. Early returns from behavior-altering therapeutics are promising, with innovations such as insomnia treatment through gamification of digitally administered cognitive behavioral therapy<sup>8</sup>. Other digital therapeutics complement existing treatments (e.g., insulin therapy), making existing therapeutic area leaders the partners of choice for many challengers. Clinical applications are abundant, and preventative digital therapeutics will have a long runway and support from cost-minded payers.



With COVID-19, we see increases in mental health issues<sup>9</sup>, opioid addictions<sup>10</sup>, and insomnia.<sup>11</sup> Digital therapeutics for these conditions could be attractive for physicians with limited patient access—driving adoption.

#### **Customized treatments and precision intervention**

Drug efficacy (or lack thereof) for given individuals is nothing new.<sup>12</sup> Many pharmaceutical and medical-device therapies are based on safety and efficacy in a large patient cohort.

Going forward, genetic sequencing, coupled with empowered and educated patients, will lead to many new, personalized therapies, such as genetic profile archetypes. As more effective therapies emerge, incumbents and their products may face shrinking demand, and skilled genomic sequencing and sample processing is likely to surge.

#### **Decision support**

The number and quality of decision support tools is projected to grow materially in the next decade. While there are numerous tools to help inform clinical decision-making today, including pulse oximetry and certain biomarkers, advanced tools have surfaced within oncology, with products able to predict the responsiveness of certain tumors to chemotherapy based on genomic mapping<sup>13</sup>, reducing both economic and quality-of-life costs for thousands of patients. Additionally, ML is adept at deciphering trends from imaging. Promising early evidence suggests that AI can detect certain types of cancer<sup>14</sup> and determine whether expensive immunotherapies are working on patients<sup>15</sup>.

COVID-19 immediately put these tools at the forefront for both physicians and businesses. A number of challengers are exploring potential use cases in adjacent or new markets to rapidly gain entry into decision support; recently, a wearable device company that had created a smart ring to measure physiological attributes such as sleep, respiratory rates, and temperature, customized the device to preemptively identify potential COVID infections in at-risk athletes<sup>16</sup>.

#### **Prevention and early detection**

Much of the world's patient-physician interactions remain in-person, occasionally augmented by calls, texts, or emails. However, COVID-19 has created demand for care delivered from home, forcing HC systems to establish virtual coverage.

Patients have become comfortable with telehealth, which should lead to increased receipt of care and potentially better disease monitoring. Additionally, remote monitoring and diagnostics could enable earlier detection of both acute and chronic issues. From an industry perspective, existing regimens and product utilization could grow or decline, and new targets may be accessible. LS incumbents can look to partner with telemedicine providers to develop remote diagnostics to capitalize on this trend.

#### **Implications for LS executives**

There is no one-size-fits-all solution for LS organizations; however, as a leader, you should consider the following questions:



Have I given my organization the right guidance and vision to capitalize on convergence?

Am I making the **right investments** to move my organization to the future paradigm?


Am I allowing my teams to "fail fast" and learn from the rapidly advancing technology landscape?



#### How to handle convergence

Given the visible impact of convergence in LS, executives will experience increasing pressure to act. As such, we have identified four response strategies inspired by other industries that have experienced convergence in the form of e-commerce, fintech, and advertising.

Figure 5. Response strategies above



#### Become even better at what you do best

In order to stave off competition from challengers, incumbents often benefit by investing in what they do best, viewing technology as a complementary asset rather than reinventing their core businesses. Large wholesale clubs have grown their brick-and-mortar footprints, while e-commerce has disrupted most others. Wholesale clubs, based on their size, negotiating power, and membership income, continue to provide customers with products that are often sold at prices that are simply not economically feasible for e-commerce merchants. They have leveraged their unique market positioning to become even better at what they do best.

Similarly, financial services incumbents, to keep up with competitive entrants offering sleek, online digital products, have invested heavily in their credit card businesses, striking partnerships with key hotels and airlines that have helped make many large banks a one-stop shop for all financial services needs and retaining customers through convenience and partnerships that smaller challengers could not establish.

#### Be the leader by acquiring the leader

In addition to investing in strengths, incumbents have successfully acquired the capabilities of convergence firms to defend their market leadership. Continuously "sensing" the disruptor landscape, identifying the right companies, and integrating strategically has proven a successful approach to capitalize on convergence and preserve the disruptor's unique assets (which we have discussed in depth previously<sup>17</sup>).

One leading payments provider acquired a credit card payment system management company, gaining market leadership for the new world of e-commerce. A similar story played out in retail, where one leading company acquired an online same-day delivery platform in order to bolster its shipping capabilities against online disruptors. This company's e-commerce sales have increased more than 70% since 2017.

#### New uses for existing assets

Acquiring leading capabilities and investing in strengths can help incumbents mitigate competitive pressures, but it can be costly. Incumbents have also changed their monetization strategies and the way they see their assets, a strategy that allowed a leading media outlet to leverage its strong brand and reputation to pivot from advertising-based revenue to an online subscription model and survive convergence.

#### **Open for business**

Finally, another viable way of mitigating pressure from new challengers is to partner with them or join an ecosystem. This can involve granting competitors or challengers to access your assets or data in a way that may previously have been considered a competitive differentiator.

For example, a leading footwear and apparel company gave retail and brand partners access to a supply chain tool, enabling better-informed pricing and promotion decisions. This required all companies to share "commercially sensitive" data, but, in practice, led to a better view of global inventory and increased sales. Similarly, many retailers have opened online platforms for sellers to list goods and reach a larger number of buyers, realizing significant growth and new ways to generate value as a result.

#### **Implications for LS**

By investing in strengths, acquiring leading capabilities, changing the way incumbents view their assets, and opening up their business, several organizations outside the LS industry have successfully defended their market position. These strategies may provide pathways to reimagine LS business models, thrive, and survive convergence.

Investing in leading capabilities could be handled by setting up a "sensing engine" or vehicle to make minority investments in new, promising capabilities and disruptors, letting incumbents stay close to disruptors and subsequently acquire the most mature players or capabilities. As such, incumbents should consider venture funds or early-stage partnerships to explore emerging technologies.

LS companies have many unique assets (access to key call points across the patient care continuum, disease-state knowledge, robust regulatory processes, and more) that can expand their business models. Partnering or acquiring challengers that are able to build off these assets, or creating new models internally, allows for test pilots in select markets to see if these new models can gain traction.

Finally, participating in or creating an ecosystem around existing assets may advance product development or commercialization or strengthen manufacturing and supply chain capabilities. The emergence of ecosystems has proven to be equally as disruptive as new market entrants<sup>18</sup>.

Ultimately, though disruption in LS may not mirror retail, finance, and advertising, there will be plenty of opportunities for challengers to change competitive dynamics and threaten the position of market leaders.

### Contacts

To begin a discussion, or for further information on convergence in life sciences, please contact:

#### **Mike DeLone**

Principal Deloitte Consulting LLP Mobile: +1 215 299 5230 Email: mdelone@deloitte.com

#### Varun Budhiraja

Principal Deloitte Consulting LLP Mobile: +1 818 441 4455

#### **Kushan Biswas** Senior manager

Deloitte Consulting LLP Mobile: +1 812 369 9038

#### **Michiel ten Broeke** Manager

Deloitte Consulting LLP Mobile: +1 628 205 5950 Email: vbudhiraja@deloitte.com Email: kbiswas@deloitte.com Email: mitenbroeke@deloitte.com

We also wish to thank **RJ Towner** and **Olivia Houston** who contributed their ideas and insights to this paper.

## Endnotes

1 Tom Yang, Sonal Shah, and Christine Yang, "The future of biopharma: Reimagining traditional business models in 2040," Deloitte Insights, March 23, 2020, https://www2.deloitte.com/us/en/insights/industry/health-care/future-of-pharmaceutical-industry.html.

2 Pedro Arboleda, Jay Zhu, "Six winning roles for medtech to thrive in the future of health," Deloitte, January 11, 2020, https://www2.deloitte. com/us/en/pages/life-sciences-and-health-care/articles/medical-technology-trends-six-winning-roles.html.

3 Richard Waters, "Big Tech searches for a way back into healthcare," Financial Times, May 16, 2020, https://www.ft.com/content/74be707e-6848-11ea-a6ac-9122541af204.

4 Crunchbase, Crunchbase Deal Data, August 2020, https://www.crunchbase.com.

5 Megan Scudellari, "The sprint to solve coronavirus protein structures — and disarm them with drugs," Nature, last updated May 19, 2020. 6 Alex Keown, "An AI First: Deep Genomics Platform Reveals Wilson's Disease Drug Candidate," BioSpace, September 26, 2019, https://www. biospace.com/article/deep-genomics-ai-program-reveals-first-drug-candidate-for-wilson-s-disease.

7 Deloitte, "Digital therapeutics: Improving patient outcomes through convergence," https://www2.deloitte.com/us/en/pages/life-sciencesand-health-care/articles/digital-therapeutics.html.

8 Betty Pfefferbaum and Carol S. North, "Mental Health and the Covid-19 Pandemic," New England Journal of Medicine 383 (August 2020): pp. 510–512. https://www.nejm.org/doi/full/10.1056/NEJMp2008017.

9 Pear Therapeutics, "reSET® & reSET-O®," https://www.peartherapeutics.com/products/reset-reset-o.

10 Marcelina Jasmine Silva and Zakary Kelly, "The Escalation of the Opioid Epidemic Due to COVID-19 and Resulting Lessons About Treatment Alternatives," American Journal of Managed Care 26, no. 7 (June 2020): pp. 202–204.

11 Theresa Machemer, "Insomnia and Vivid Dreams on the Rise With COVID-19 Anxiety," Smithsonian Magazine, April 23, 2020, https://www. smithsonianmag.com/smart-news/insomnia-and-vivid-dreams-rise-pandemic-anxiety-180974726.

12 Hans-Georg Eichler et al., "Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response," Nature Reviews Drug Discovery 10 (July 2011): pp. 495–506.

13 oncotypelQ, "Smarter Cancer Care," https://www.oncotypeiq.com/en-US.

14 Neil Savage, "How AI is improving cancer diagnostics," Nature, March 25, 2020, https://www.nature.com/articles/d41586-020-00847-2.

15 Michael Eisenstein, "Al Brings Precision to Cancer Immunotherapy," Genetic Engineering & Biotechnology News, April 2020, https://www.genengnews.com/magazine/april-2020-vol-40-no-4/supplement-april-2020-vol-40-no-4/ai-brings-precision-to-cancer-immunotherapy.

16 Oura, "Oura Partners With the NBA and WNBA," https://support.ouraring.com/hc/en-us/articles/360050735433-Oura-Partners-With-the-NBA-and-WNBA.

17 Deloitte, "Life sciences transformation powered by external innovation," https://www2.deloitte.com/us/en/pages/mergers-and-

acquisitions/articles/life-sciences-mergers-and-acquisitons-external-tech-innovation-and-transformation.html.

18 Deloitte, "Thriving in a world of ecosystems," https://www2.deloitte.com/us/en/pages/operations/articles/business-ecosystems.html.

#### About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see <a href="https://www.deloitte.com/about">www.deloitte.</a> com/about to learn more about our global network of member firms.